These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 35130235)

  • 1. Colchicine in the management of Covid-19: With or lieu of evidence.
    Al-Kuraishy HM; Hussien NR; Al-Niemi MS; Al-Gareeb AI
    J Pak Med Assoc; 2021 Dec; 71(Suppl 8)(12):S127-S132. PubMed ID: 35130235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
    Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G
    J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19.
    Al-Kuraishy HM; Al-Gareeb AI; Mostafa-Hedeab G; Kasozi KI; Zirintunda G; Aslam A; Allahyani M; Welburn SC; Batiha GE
    Front Immunol; 2021; 12():749291. PubMed ID: 34867978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitazoxanide and COVID-19: A review.
    Al-Kuraishy HM; Al-Gareeb AI; Elekhnawy E; Batiha GE
    Mol Biol Rep; 2022 Nov; 49(11):11169-11176. PubMed ID: 36094778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study.
    Mareev VY; Orlova YA; Plisyk AG; Pavlikova EP; Akopyan ZA; Matskeplishvili ST; Malakhov PS; Krasnova TN; Seredenina EM; Potapenko AV; Agapov MA; Asratyan DA; Dyachuk LI; Samokhodskaya LM; Mershina ЕА; Sinitsyn VE; Pakhomov PV; Zhdanova EA; Mareev YV; Begrambekova YL; Kamalov АА
    Kardiologiia; 2021 Mar; 61(2):15-27. PubMed ID: 33734043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colchicine and SARS-CoV-2: Management of the hyperinflammatory state.
    Vitiello A; Ferrara F
    Respir Med; 2021 Mar; 178():106322. PubMed ID: 33550151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A raising dawn of pentoxifylline in management of inflammatory disorders in Covid-19.
    Mostafa-Hedeab G; Al-Kuraishy HM; Al-Gareeb AI; Jeandet P; Saad HM; Batiha GE
    Inflammopharmacology; 2022 Jun; 30(3):799-809. PubMed ID: 35486310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 in patients with gout on colchicine.
    Pelechas E; Drossou V; Voulgari PV; Drosos AA
    Rheumatol Int; 2021 Aug; 41(8):1503-1507. PubMed ID: 34089357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ursolic acid and SARS-CoV-2 infection: a new horizon and perspective.
    Al-Kuraishy HM; Al-Gareeb AI; Negm WA; Alexiou A; Batiha GE
    Inflammopharmacology; 2022 Oct; 30(5):1493-1501. PubMed ID: 35922738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Covid-19 and development of heart failure: mystery and truth.
    Onohuean H; Al-Kuraishy HM; Al-Gareeb AI; Qusti S; Alshammari EM; Batiha GE
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Oct; 394(10):2013-2021. PubMed ID: 34480616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Storm at the Time of Corona: A Glimpse at the Current Understanding and Therapeutic Opportunities of the SARS-CoV-2 Cytokine Storm.
    Torabi-Rahvar M; Rezaei N
    Curr Pharm Des; 2021; 27(13):1549-1552. PubMed ID: 33238863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pentoxifylline and Oxypurinol: Potential Drugs to Prevent the
    López-Iranzo FJ; López-Rodas AM; Franco L; López-Rodas G
    Curr Pharm Des; 2020; 26(35):4515-4521. PubMed ID: 32787748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of berberine in Covid-19: potential adjunct therapy.
    Babalghith AO; Al-Kuraishy HM; Al-Gareeb AI; De Waard M; Al-Hamash SM; Jean-Marc S; Negm WA; Batiha GE
    Inflammopharmacology; 2022 Dec; 30(6):2003-2016. PubMed ID: 36183284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colchicine anti-inflammatory therapy for non-intensive care unit hospitalized COVID-19 patients: results from a pilot open-label, randomized controlled clinical trial.
    Haroon MZ; Farooq U; Ashraf S; Zeb S; Gillani SY; Malik S; Ali R; Irshad R; Mehmood Z; Abbas Y; Masood A; Ghafoor A; Khalil AT; Asif H; Khan S; Ujjan ID; Nigar R; Livingstone S; Pascual-Figal DA; Togni S; Allergini P; Riva A; Khan A
    J Physiol Pharmacol; 2022 Jun; 73(3):. PubMed ID: 36302537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Proactive anti-inflammatory and anticoagulant therapy in the treatment of advanced stages of novel coronavirus infection (COVID-19). Case Series and Study Design: COLchicine versus ruxolitinib and secukinumab in open prospective randomIzed trial (COLORIT)].
    Mareev VY; Orlova YA; Pavlikova EP; Akopyan ZA; Matskeplishvili ST; Plisyk AG; Seredenina EM; Potapenko AV; Malakhov PS; Samokhodskaya LM; Mershina ЕА; Sinitsyn VE; Asratyan DA; Zhdanova EA; Mareev YV; Begrambekova YL; Shatochina EA; Kamalov АА
    Kardiologiia; 2020 Oct; 60(9):4-21. PubMed ID: 33131470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
    Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
    J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibody therapy in COVID-19.
    Conti P; Pregliasco FE; Calvisi V; Caraffa Al; Gallenga CE; Kritas SK; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(2):423-427. PubMed ID: 33904269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 immunopathology with emphasis on Th17 response and cell-based immunomodulation therapy: Potential targets and challenges.
    Pourgholaminejad A; Pahlavanneshan S; Basiri M
    Scand J Immunol; 2022 Feb; 95(2):e13131. PubMed ID: 34936112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.